EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Akeso's Enterprise Value is HK$70,825 Mil.
Akeso's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-834 Mil. Therefore, Akeso's EV-to-FCF for today is -84.94.
The historical rank and industry rank for Akeso's EV-to-FCF or its related term are showing as below:
HKSE:09926'
s EV-to-FCF Range Over the Past 10 Years
Min: -123.23 Med: -15.05 Max: 34.57
Current: -84.94
During the past 7 years, the highest EV-to-FCF of Akeso was 34.57. The lowest was -123.23. And the median was -15.05.
HKSE:09926's EV-to-FCF is ranked worse than 100% of 448
companies
in the Biotechnology industry
Industry Median: 2.13
vs HKSE:09926: -84.94
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2025-04-21), Akeso's stock price is HK$82.95.
Akeso's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.643. Therefore, Akeso's PE Ratio (TTM) for today is At Loss.
Akeso EV-to-FCF Historical Data
The historical data trend for Akeso's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Akeso's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akeso's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akeso's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Akeso's EV-to-FCF falls into.
Akeso's current Enterprise Value is HK$70,825 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Akeso's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-834 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akeso (HKSE:09926) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Akeso's share price for today is HK$82.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Akeso's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.643.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Akeso EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Akeso's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in USA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09926 has been successfully added to your 